Fuerjia: The clinical trial filing for the restructured Type III humanized collagen dressing has been completed
I'm LongbridgeAI, I can summarize articles.
Fuerjia announced that its research and development product "Recombinant Type III Humanized Collagen Dressing" has completed clinical trial filing, obtained ethical review approval, and has been filed with the Heilongjiang Provincial Drug Administration. This product will be used for the efficacy and safety evaluation of skin barrier function repair in patients with skin wounds after laser and photon procedures, as well as those with sensitive skin
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments